Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.36M | -34.60M | -100.74M | -86.91M | -79.73M |
| Total Depreciation and Amortization | -380.00K | 610.00K | 113.00K | 117.00K | -677.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.63M | 9.71M | 9.38M | 8.00M | 6.61M |
| Change in Net Operating Assets | 81.35M | -60.33M | 15.87M | -13.86M | 460.00K |
| Cash from Operations | -23.75M | -84.61M | -75.37M | -92.65M | -73.33M |
| Capital Expenditure | -240.00K | -127.00K | -42.00K | -86.00K | -114.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -339.18M | 126.20M | 75.76M | 100.15M | -62.80M |
| Cash from Investing | -339.42M | 126.08M | 75.72M | 100.06M | -62.92M |
| Total Debt Issued | 28.88M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 345.74M | 11.07M | 764.00K | 9.42M | 36.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31.30M | -209.00K | 0.00 | -207.00K | -1.31M |
| Cash from Financing | 405.91M | 10.86M | 764.00K | 9.21M | 35.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.74M | 52.32M | 1.11M | 16.62M | -100.72M |